Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101,751 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma.
Nakagawa M, Shaffer AL 3rd, Ceribelli M, Zhang M, Wright G, Huang DW, Xiao W, Powell J, Petrus MN, Yang Y, Phelan JD, Kohlhammer H, Dubois SP, Yoo HM, Bachy E, Webster DE, Yang Y, Xu W, Yu X, Zhao H, Bryant BR, Shimono J, Ishio T, Maeda M, Green PL, Waldmann TA, Staudt LM. Nakagawa M, et al. Among authors: yang y. Cancer Cell. 2018 Aug 13;34(2):286-297.e10. doi: 10.1016/j.ccell.2018.06.014. Epub 2018 Jul 26. Cancer Cell. 2018. PMID: 30057145 Free PMC article.
Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma.
Ishio T, Kumar S, Shimono J, Daenthanasanmak A, Dubois S, Lin Y, Bryant B, Petrus MN, Bachy E, Huang DW, Yang Y, Green PL, Hasegawa H, Maeda M, Goto H, Endo T, Yokota T, Hatanaka KC, Hatanaka Y, Tanaka S, Matsuno Y, Yang Y, Hashino S, Teshima T, Waldmann TA, Staudt LM, Nakagawa M. Ishio T, et al. Among authors: yang y. Blood. 2022 Mar 10;139(10):1541-1556. doi: 10.1182/blood.2021012734. Blood. 2022. PMID: 34818414 Free PMC article.
Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas.
Chiba M, Shimono J, Ishio T, Takei N, Kasahara K, Ogasawara R, Ara T, Goto H, Izumiyama K, Otsuguro S, Perera LP, Hasegawa H, Maeda M, Hashino S, Maenaka K, Teshima T, Waldmann TA, Yang Y, Nakagawa M. Chiba M, et al. Among authors: yang y. Blood. 2022 Nov 3;140(18):1951-1963. doi: 10.1182/blood.2022015646. Blood. 2022. PMID: 35921533 Free PMC article.
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.
Barta SK, Zain J, MacFarlane AW 4th, Smith SM, Ruan J, Fung HC, Tan CR, Yang Y, Alpaugh RK, Dulaimi E, Ross EA, Campbell KS, Khan N, Siddharta R, Fowler NH, Fisher RI, Oki Y. Barta SK, et al. Among authors: yang y. Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):356-364.e3. doi: 10.1016/j.clml.2019.03.022. Epub 2019 Apr 3. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31029646 Free PMC article. Clinical Trial.
Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.
Yang Y, Kelly P, Shaffer AL 3rd, Schmitz R, Yoo HM, Liu X, Huang DW, Webster D, Young RM, Nakagawa M, Ceribelli M, Wright GW, Yang Y, Zhao H, Yu X, Xu W, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Delabie J, Rimsza L, Staudt LM. Yang Y, et al. Cancer Cell. 2016 Apr 11;29(4):494-507. doi: 10.1016/j.ccell.2016.03.006. Cancer Cell. 2016. PMID: 27070702 Free PMC article.
101,751 results
You have reached the last available page of results. Please see the User Guide for more information.